Janux Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a US-listed clinical-stage biopharmaceutical company trading on the NASDAQ under the ticker JANX. Headquartered in San Diego, California, and incorporated in Delaware in June 2017, the company focuses on next-generation immunotherapies for cancer and, more recently, autoimmune disease. Its strategy is built around proprietary platforms designed to conditionally activate T cells in the tumor microenvironment, with the goal of preserving anti-tumor potency while reducing the systemic toxicity that has limited many earlier immunotherapy approaches. Janux’s core technology stack includes TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator), which together form the basis of a platform-driven pipeline strategy. From a business perspective, Janux remains a development-stage company with no marketed products and no product revenue to date. Its operating model is centered on R&D, translational work, and early clinical execution. The company’s lead historical program has been JANX007, a PSMA-targeted TRACTr being evaluated in prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Janux also advanced JANX008, an EGFR-targeted candidate in multiple solid tumors, while expanding its pipeline with JANX011, the first clinical asset from its ARM platform, and JANX014. The company has also highlighted autoimmune disease as a longer-term expansion opportunity, broadening its addressable market beyond oncology. In 2026, Janux announced discontinuation of the JANX008 clinical program, a reminder that pipeline management remains highly data-dependent in this sector. Competitively, Janux operates in a crowded and scientifically demanding landscape that includes bispecific antibody developers, T-cell engager specialists, and large pharmaceutical companies pursuing similar tumor-directed immune strategies. Its main differentiation thesis is that conditional, tumor-restricted activation can improve the therapeutic window and potentially support more convenient dosing regimens. In that sense, Janux is best viewed as a platform biotech rather than a single-asset company, with value creation dependent on whether its proprietary biology can repeatedly generate clinically meaningful candidates. Geographically, Janux is primarily US-based, with its main headquarters and operational footprint in San Diego, a major biotech hub. Its clinical development and investor communications are also centered on the United States. Recent milestones have been notable: in 2025 and 2026 the company reported multiple pipeline and clinical updates, announced an exclusive worldwide collaboration with Bristol Myers Squibb in January 2026, disclosed a clinical milestone in its Merck collaboration, dosed the first participant in the JANX011 Phase 1 study in February 2026, and later announced the discontinuation of JANX008 in April 2026. For investors, JANX remains a high-risk, high-upside oncology and immunology platform story driven by clinical readouts, partner validation, and disciplined portfolio progression.